AstraZeneca’s Next-Gen PARP Inhibitor Hints At Better Safety And Efficacy In Breast Cancer

 
• By Andrew McConaghie
  
San Diego
The San Diego Convention Center is hosting this year's AACR congress.

More from Clinical Trials

More from R&D